Melissa Johnson

Melissa Johnson is a thoracic oncologist at Sarah Cannon Research Institute who has been involved in early-phase development of multiple first-line immunotherapy combinations for NSCLC across community and academic settings. Her work on dose-finding studies and early-phase trials has contributed to the development pipeline of next-generation IO agents in lung cancer. She participates in ASCO, WCLC, and SITC annual meetings presenting novel IO combination data. Johnson advocates for broadening clinical trial access in community oncology settings for patients with advanced NSCLC.